NEW YORK, NY--(Marketwire -03\/05\/12)- February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming the S&P 500 by close to 17 percent over that time frame. Despite the drop in investor optimism, new and promising research continues to propel the industry forward. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on BioTime, Inc. (AMEX: BTX - News) and Aastrom Biosciences, Inc. (NASDAQ: ASTM - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.fivestarequities.com\/BTX<\/a> <\/p>\n http:\/\/www.fivestarequities.com\/ASTM<\/a> <\/p>\n A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. \"This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it,\" Eduardo Marban, director of the Cedars-Sinai Heart Institute and one of the study's co-authors, said in a statement. \"The effects are substantial.\" <\/p>\n In another study, researchers led by Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital, argue they've discovered the ovaries of young women harbor very rare stem cells capable of producing new eggs. <\/p>\n Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.fivestarequities.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. <\/p>\n BioTime, Inc. primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. The company recently elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois. <\/p>\n Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.fivestarequities.com\/disclaimer<\/a> <\/p>\n<\/p>\n Link: NEW YORK, NY--(Marketwire -03\/05\/12)- February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming the S&P 500 by close to 17 percent over that time frame. Despite the drop in investor optimism, new and promising research continues to propel the industry forward Continue reading
\nBioTime and Aastrom Biosciences -- Stem Cell Research Making Breakthroughs<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"